Decreasing SIL1-R2 concentration could enhance the expression oftranscription factors on the gene level

Abstract

By the time you opened this document, an individual somewhere in the world has developed Alzheimer’s disease. With over 6 million cases in the United States alone and a global total exceeding 50 million, Alzheimer’s contributes to around one-third of senior fatalities. Horrifyingly, according to the United Nations, the number of patients doubles every two decades if a breakthrough is not discovered. Therefore, it is imperative to the survival of the human species to address and attempt to solve this issue before it can escalate any further. In this work, I have designed a few experiments that could be monumental to developing future Alzheimer’s vaccines and medicine. The primary focus of the trials above is to explore the possible role of the IL-1 signaling protein in the Bace-1- 1 deletion process to the potential prevention of DAM-2 formation, which, in turn, could worsen Alzheimer’s symptoms. The overall prediction can be summed up in the following: The activation of the IL-1 signaling pathway will enhance the activity of TF and lead to the up-regulation of TF gene expression. If my assumption is proven correct, it could pave the way for future Alzheimer’s medication to include drugs that moderate IL-1 signaling, which could save countless amount of lives.